Genprex Secures Key Japanese and EU Patents for Cancer Gene Therapy Combinations
Event summary
- Genprex received patent grants from Japan and the EU for Reqorsa® gene therapy combined with immunotherapies to treat cancer.
- The patents cover combinations with PD-L1 and PD-1 antibodies, strengthening Genprex's global IP portfolio.
- Acclaim-3 clinical trial for small cell lung cancer (SCLC) is a key focus, combining Reqorsa® with Genentech's Tecentriq®.
- Phase 2 expansion of Acclaim-3 aims to enroll 50 patients, with interim analysis expected in the second half of 2026.
- Genprex already holds patents in the U.S., Korea, and other regions for similar combinations.
The big picture
Genprex's patent wins in Japan and the EU fortify its position in the competitive oncology gene therapy space, particularly for SCLC. The strategic move aligns with broader industry trends toward combination therapies, where gene therapies are paired with immunotherapies to enhance efficacy. The Acclaim-3 trial's progress will be critical in validating this approach, potentially opening new market opportunities in key regions.
What we're watching
- Clinical Trial Progress
- The pace at which Genprex completes enrollment and interim analysis in the Acclaim-3 trial will signal the viability of Reqorsa® in combination therapies.
- IP Portfolio Expansion
- Whether Genprex can sustain its global IP strategy by securing additional patents in pending regions like Australia.
- Regulatory Pathways
- How FDA Fast Track and Orphan Drug designations will influence the regulatory approval process for Reqorsa®.
Related topics